|
Name |
Callitrin
|
Molecular Formula | C15H22O2 | |
IUPAC Name* |
(3R,3aR,5R,6R,7aR)-6-ethenyl-3,6-dimethyl-5-prop-1-en-2-yl-3,3a,4,5,7,7a-hexahydro-1-benzofuran-2-one
|
|
SMILES |
C[C@@H]1[C@H]2C[C@@H]([C@@](C[C@H]2OC1=O)(C)C=C)C(=C)C
|
|
InChI |
InChI=1S/C15H22O2/c1-6-15(5)8-13-11(7-12(15)9(2)3)10(4)14(16)17-13/h6,10-13H,1-2,7-8H2,3-5H3/t10-,11-,12-,13-,15+/m1/s1
|
|
InChIKey |
HHMGIPSZHRMYCD-HVNMYJMUSA-N
|
|
Synonyms |
Callitrin; (3R,3aR,5R,6R,7aR)-3,6-Dimethyl-5-(prop-1-en-2-yl)-6-vinylhexahydrobenzofuran-2(3H)-one; 2(3H)-Benzofuranone, 6-ethenylhexahydro-3,6-dimethyl-5-(1-methylethenyl)-, (3R,3aR,5R,6R,7aR)-; 2(3H)-Benzofuranone, 6-ethenylhexahydro-3,6-dimethyl-5-(1-methylethenyl)-, [3R-(3.alpha.,3a.alpha.,5.alpha.,6.beta.,7a.alpha.)]-; 66964-63-4
|
|
CAS | NA | |
PubChem CID | 14038380 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 234.33 | ALogp: | 4.2 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 17 | QED Weighted: | 0.531 |
Caco-2 Permeability: | -4.613 | MDCK Permeability: | 0.00002990 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.119 | Plasma Protein Binding (PPB): | 80.08% |
Volume Distribution (VD): | 1.631 | Fu: | 25.17% |
CYP1A2-inhibitor: | 0.144 | CYP1A2-substrate: | 0.278 |
CYP2C19-inhibitor: | 0.126 | CYP2C19-substrate: | 0.865 |
CYP2C9-inhibitor: | 0.082 | CYP2C9-substrate: | 0.402 |
CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.495 |
CYP3A4-inhibitor: | 0.859 | CYP3A4-substrate: | 0.462 |
Clearance (CL): | 2.773 | Half-life (T1/2): | 0.228 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.437 |
Drug-inuced Liver Injury (DILI): | 0.447 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.057 | Maximum Recommended Daily Dose: | 0.147 |
Skin Sensitization: | 0.408 | Carcinogencity: | 0.114 |
Eye Corrosion: | 0.567 | Eye Irritation: | 0.895 |
Respiratory Toxicity: | 0.828 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001925 | 0.400 | D0K7LU | 0.288 | ||||
ENC001895 | 0.400 | D0S3WH | 0.247 | ||||
ENC003248 | 0.353 | D04SFH | 0.228 | ||||
ENC003099 | 0.338 | D0G6AB | 0.216 | ||||
ENC003670 | 0.328 | D0I2SD | 0.202 | ||||
ENC003551 | 0.324 | D03UQM | 0.200 | ||||
ENC003753 | 0.321 | D07BSQ | 0.198 | ||||
ENC002226 | 0.313 | D0P0HT | 0.194 | ||||
ENC000782 | 0.313 | D0D2TN | 0.192 | ||||
ENC003480 | 0.311 | D08PIQ | 0.192 |